CD8A and neoplasm: To gain an understanding of the TCR diversity of the tumor-reactive T cell response detected in HR+ breast cancer patients, we performed TCR sequencing of the tumor-reactive CD8 T cell lines generated from the blood of 15 patients that had a detectable circulating antitumor T cell response.